Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Investor Presentation (March 2026)
15 slides from Poly Medicure's investor presentation, Mar 7, 2026
Slide 1: Submission of Investor's Presentation cover letter
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi· 110 020 (INDIA) :» IPOLYMED T: +91-11- 33550700, 47317000 E: info@polymedicure.com W: polymedicure.com CIN: L 40300DL l 995PLC066923 Date: 07th March, 2026 Scrip Code: - 531768 Scrip Code: - POLYMED
Slide 2: Investor Presentation March 2026
Investor Presentation March 2026 1
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as
Slide 4: Polymed Group – A Unique Medical Devices Platform
Polymed Group – A Unique Medical Devices Platform 13 225+ Specialities Medical Devices 15 125+ Manufacturing Plants Across 5 countries Countries 3600+ 570+ Employee Base Sales Associates 390+ 950+ Distributors across Patents Granted India & Globally 1.8 Billion+ Largest Exporter Devices Manufacturin
Slide 5: Polymed Flywheel
Polymed Flywheel In-House Product R&D Clinical Engagement • 390+ patents; 30+ new products launches 60+ clinical experts; 4,000+ annual • 100+ R&D professionals in India and customer engagement programs Europe globally Distribution Network Tooling , Automation, rapid • 950+ distributors globally pro
Slide 6: Moving Up the Technology Curve & Increasing TAM in High Growth Areas
Moving Up the Technology Curve & Increasing TAM in High Growth Areas Infusion Therapy (1997) Global Leadership, 3rd largest IV cannula 10% manufacturer globally Size of the bubble reflects relative global industry size 9% Renal Care (2018) 8% First Indian company to indigenously manufacture dialysis
Slide 7: Driving Value Through Strategic Acquisitions
Driving Value Through Strategic Acquisitions Founded in 2011, Located in Leek Founded in 1962, Located in Bologna, Italy Founded in 1995, Located in Amaro, Italy Netherlands EN ISO 13485:2003 certified ISO 9001, ISO 13485 and FDA certified ISO 13485 and FDA certified Products Compliant with EU MDR a
Slide 8: Key Strategic Updates
Key Strategic Updates • 2nd plant at Haridwar now commercially operational augmenting capacity for domestic • Market • Plant at Palwal, Haryana to be completed by end of FY 27 –increases capacity for Blood Infrastructure Bags (50%) and infusion products • YEIDA (near new Greater Noida Airport) land
Slide 9: International Growth Strategy – US
International Growth Strategy – US Entity Polymed Citieffe Pendracare P1H Presence 4 distributors Direct Presence Guiding catheter NA approved; In talks with distributors and # Regulatory 4 approved; 3- 10 approved; 8-10 global OEM; sales expected to start in 1 approved for OEM Approvals 4 in pipeli
Slide 10: International Strategy – Europe
International Strategy – Europe Entity Polymed Citieffe Pendracare P1H Direct presence in 17 distributors + 2 Presence 75+ distributors 20+ distributors Italy + 12 Distributors OEM relationship # Regulatory 82 approved; Whole Portfolio (20+); 2 approved; 3 Whole Portfolio (4 Approvals 15 in pipeline
Slide 11: Domestic Growth Strategy
Domestic Growth Strategy Substituting imports with high quality Made in India products Import Ø Proven capabilities in Infusion Therapy & Vascular Access Focused Therapy Areas Substitution Infusion · Renal · Cardiology · Critical Care Ø Replicating success across Renal, Cardiology and Critical Care
Slide 12: Financial Performance Summary
Financial Performance Summary Figs in Rs. Cr. unless specified Standalone Consolidated Particulars 9M FY 26 9M FY 25 YoY Growth % 9M FY 26 9M FY 25 YoY Growth % Revenue from Operations 1219.4 1180.8 3.3% 1340.7 1229.0 9.1% Cost of Good Sold 382.6 387.9 (1.3%) 418.6 407.3 2.8% Gross Profit 836.8 793.
Slide 13: Consolidated Sales Performance Analysis
Consolidated Sales Performance Analysis Figs in Rs. Crs unless specified Particulars 9M FY 26 9M FY 25 YoY Growth % Revenue Mix by Segment Domestic 413.0 351.3 17.6% 30% 26% International 918.1 868.0 5.8% 10% 9% Others Other Operating Revenue 9.5 9.8 (2.2%) 60% 65% Renal Infusion Therapy Total Opera
Slide 14: Polymed- One Company. Many Engines of Growth
Polymed- One Company. Many Engines of Growth Strong Management Large TAM & Governance framework US$ 650bn global Medtech Experienced leadership and market growing ~5%; India board driving strong market growing ~13% governance Robust Financial Strong Manufacturing performance Capabilities 22% sales C
Slide 15: Thank You
Thank You For any investor related queries reach us at: investocare@polymedicure.com 14